EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In Vivo Immunoscoring Technique to Monitor Anti‐ CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer

Minfeng Yang iD, Shiqiang Hou iD, Chi Ming Wong iD, Hongzhao Chen, Chunjin Jin iD, Song-Bai Liu, Jung Sun Yoo iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Minfeng Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Nantong University, Nantong, China. Hauptthemen laut MEDLINE: CD47 Antigen, Triple Negative Breast Neoplasms, Immunotherapy. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Collaborative Research Fund from the Research Grants Council of Hong Kong SAR, the Program of Youth Project of the Natural Science Foundation of Nantong, Basic Research Program of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phagocytosis checkpoints, such as CD47, have emerged as promising targets for cancer immunotherapy and are being investigated in clinical trials. Despite encouraging findings, reliable biomarkers for monitoring immunotherapeutic responses in triple‐negative breast cancer (TNBC) remain tracking.

Objective

The objective of this project is to characterize the functional states of tumor‐associated macrophages (TAMs) using macrophage‐related imaging probes and assess their potential for monitoring responses to anti‐CD47 immunotherapy.

Results

Anatomical imaging visualized tumor nodule formation and angiogenesis in tumor‐bearing mice. Conventional fluorescence imaging demonstrated the TNBC‐targeting ability of monocyte chemoattractant protein‐1 (MCP‐1) fluorescein isothiocyanate (FITC) and Dextran‐Alexa Fluor 680 (AF 680). Intravital imaging elucidated the pharmacokinetics of the imaging probes in TAMs following intravenous injection. These probes preferentially targeted macrophages, as confirmed by the colocalization between F4/80‐, CD86‐, and CD206‐binding cells and imaging probe‐targeted cells. Tumor‐bearing mice that received intravenous injections of the imaging probes were sacrificed, and the TNBC tissue was cryo‐sectioned, stained, and imaged on a confocal microscope, showing a high molecular targeting ability of the imaging probes for macrophages. The M1/M2 macrophage ratio was quantified for monitoring the response to anti‐CD47 immunotherapy, which demonstrated that MCP‐1 and Dextran are useful tools for M1 and M2 macrophage identification.

Conclusion

The study documents a molecularly targeted construct for TAMs in vivo and verifies proof of the utility of using the M1/M2 ratio as a strategy for monitoring the response to CD47 treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenTriple Negative Breast NeoplasmsImmunotherapyAnimalsFemaleHumansMiceCell Line, TumorChemokine CCL2Tumor-Associated MacrophagesMacrophagesXenograft Model Antitumor Assays

Stichwörter der Autor:innen

MCP1‐FITCanti‐CD47 immunotherapydextran‐AF680intravital imagingtumor‐associated macrophages

Substanzen

CD47 AntigenChemokine CCL2CD47 protein, human

Autor:innen und Institutionen

  • School of Public Health, Nantong University, Nantong, China.
  • The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou, China.
  • Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.
  • Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China.

ORCID-Profile: Minfeng Yang, Shiqiang Hou, Chi Ming Wong, Chunjin Jin, Jung Sun Yoo

Förderung

  • Collaborative Research Fund from the Research Grants Council of Hong Kong SAR
  • the Program of Youth Project of the Natural Science Foundation of Nantong
  • Basic Research Program of Jiangsu Province
  • Jiangsu Funding Program for Excellent Postdoctoral Talent
  • General Research Fund
  • PolyU Internal Grant

Zitieren

APA

Yang, M., Hou, S., Wong, C. M., Chen, H., Jin, C., Liu, S. B., & Yoo, J. S. (2026). In Vivo Immunoscoring Technique to Monitor Anti‐ CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.72232

Vancouver

Yang M, Hou S, Wong CM, Chen H, Jin C, Liu SB, et al. In Vivo Immunoscoring Technique to Monitor Anti‐ CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer. Cancer Medicine. 2026. doi:10.1002/cam4.72232

BibTeX
@article{Yang2026,
  author = {Yang, Minfeng and Hou, Shiqiang and Wong, Chi Ming and Chen, Hongzhao and Jin, Chunjin and Liu, Song-Bai and Yoo, Jung Sun},
  title = {In Vivo Immunoscoring Technique to Monitor Anti‐ CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72232}
}
Kostenlos starten →